BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 17, 2013
View Archived Issues
Merck Serono funds new nonprofit EspeRare Foundation
Read More
Rare variant of CALCRL gene associated with diabetic nephropathy susceptibility
Read More
Intec Pharma receives Michael J. Fox Foundation grant
Read More
Japanese scientists disclose new vaccines for tuberculosis
Read More
NT-113, a pan-erbB inhibitor active against brain metastases in rodents
Read More
First-in-human results for ARQ-092 demonstrate disease stabilization in patients with solid tumors
Read More
Potential repurposing of old anti-inflammatory drug for tuberculosis
Read More
Bristol-Myers Squibb presents the discovery of novel HCV entry pathway inhibitors
Read More
Durect submits NDA for Posidur pain relief depot
Read More
Roche synthesizes new series of PDE10A inhibitors
Read More
Merck & Co. patents novel JAK1/JAK2 inhibitors
Read More
Rhythm begins phase II trial of RM-131 for lower GI function disorders
Read More
Bayer Intellectual Property discloses new anticancer agents
Read More
Aerocrine's Niox Mino device approved in Canada
Read More
Santhera to continue phase III Catena trial in DMD
Read More
FDA to consider accelerated approval for Sarepta Therapeutics' eteplirsen
Read More
Isis Innovation divulges new CB2 receptor agonists
Read More
Meiji Seika Pharma acquires Japanese rights to asenapine
Read More
New agents inhibiting CYP11B2 disclosed by Merck & Co.
Read More
Eli Lilly reports data from phase III trials of dulaglutide in type 2 diabetes
Read More
Authorities expand European approval of Berinert in HAE
Read More
First patient enrolled in global phase III program for Amikacin Inhale
Read More
Zymeworks achieves second milestone in collaboration with Merck & Co.
Read More
AnGes and Shionogi agree to begin phase I testing of NF-kappaB decoy oligodeoxynucleotide
Read More
Topline results reported from phase II study of GMI-1070
Read More
